​These highly novel findings are important in that targeting MUC1-C represents an approach for the epigenetic reprogramming of human cancer.

​Genus announces the appointment of key opinion leaders Drs. Helen Sabzevari, former head of Immunotherapy at EMD and Ralph Weichselbaum, Professor at University of Chicago, as members of the Genus Scientific Advisory Board.

​Genus Oncology collaborates with leaders in leukemia research at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center on an investigator-initiated Phase 1b/2a trial of GO-203 in combination with Decitabine for the treatment of patients with relapsed/refractory AML.

​Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML.

​Targeting of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung cancer.  Study published in “Cancer Research”.  These findings demonstrate that targeting MUC1-C is a novel approach for downregulating MYC expression in MYC-dependent carcinomas.

​Studies published in “Blood” demonstrate that MUC1-C drives MYC expression in multiple myeloma.  These findings are of importance in that GO-203 treatment represents a novel therapeutic approach to target MYC in multiple myeloma cells that are addicted to MYC for their growth and survival.

​Genus receives orphan drug designation from the US FDA for GO-203 treatment of relapsed/refractory Acute Myeloid Leukemia (AML).

​Preclinical results of MUC1-C-targeted GO-203/nanoparticles published in the journal “Clinical Cancer Research”.  These findings define an approach for sustained administration of GO-203 in novel polymeric tetra block nanoparticles to target MUC1-C in human cancers.